0.000240365355340126 -0.000240365355340126 0.000440669818123602 0.00172261837993753 0.00560852495793609 0.00945437064337799 0.00833266565179077 0.0067302299495233
Sign Up Today X
Thanks for submitting the form.
Stockreport

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer [Yahoo! Finance]

Illumina, Inc. (ILMN)  More Company Research Source: Yahoo! Finance
Last illumina, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: illumina.com/company/investor-information.html
AGIO announced that the FDA has granted orphan drug designation to its novel pyruvate kinase (PK) activator, tebapivat, for the treatment of myelodysplastic syndromes (MDS), a rare type of blood cancer. The FDA generally grants orphan drug designation to investigational therapies that address rare medical diseases or conditions affecting fewer than 200,000 people in the United States. The perquisites that come from this designation include assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity upon potential approval. Agios is developing tebapivat (formerly, AG-946), its PK activator candidate, as a potential treatment for MDS and hemolytic anemias. The company is currently starting a phase IIb study on tebapivat for treating lower-risk MDS. It has already achieved clinical proof-of-concept in a phase IIa study on tebapivat as a potential treatment for anemia in lower-risk MDS. Share [Read more]
IMPACT SNAPSHOT EVENT TIME: ILMN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ILMN alerts
from News Quantified
ILMN
NEWS
ILMN
Earnings
ILMN
Analyst Actions
ILMN
SEC Filings
Stockreport

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer [Yahoo! Finance]

Illumina, Inc.  (ILMN) 
More Company Research Source: Yahoo! Finance
Last illumina, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: illumina.com/company/investor-information.html
AGIO announced that the FDA has granted orphan drug designation to its novel pyruvate kinase (PK) activator, tebapivat, for the treatment of myelodysplastic syndromes (MDS), a rare type of blood cancer. The FDA generally grants orphan drug designation to investigational therapies that address rare medical diseases or conditions affecting fewer than 200,000 people in the United States. The perquisites that come from this designation include assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity upon potential approval. Agios is developing tebapivat (formerly, AG-946), its PK activator candidate, as a potential treatment for MDS and hemolytic anemias. The company is currently starting a phase IIb study on tebapivat for treating lower-risk MDS. It has already achieved clinical proof-of-concept in a phase IIa study on tebapivat as a potential treatment for anemia in lower-risk MDS. Share [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ILMN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS